Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bevacizumab biosimilar - Intas Pharmaceuticals

Next Previous
Drug Profile

Bevacizumab biosimilar - Intas Pharmaceuticals

Alternative Names: Bevatas; INTP-24; Recombinant immunoglobulin G1 monoclonal antibody biosimilar - Intas Pharmaceuticals

Latest Information Update: 12 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intas Biopharmaceuticals
  • Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 25 Sep 2019 Intas Pharmaceuticals plans a phase I bioequivalence trial in Healthy volunteers in India (CTRI/2019/02/017428)
  • 15 Sep 2019 Intas Pharmaceuticals plans a phase III trial in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in India, Germany, Poland, Romania and Spain (IV) (CTRI/2019/08/020665)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top